EAST-ASIA PHARMACEUTICAL: Lu Li Kang Zuo raw materials have obtained the raw material drug registration certificate in South Korea
I'm LongbridgeAI, I can summarize articles.EAST-ASIA PHARMACEUTICAL announced that its Luliconazole active pharmaceutical ingredient has obtained the registration certificate from the Korea Food and Drug Administration. This certification marks the product's eligibility for entry into the South Korean market, which will positively impact the company's expansion in the pharmaceutical market in South Korea and promote the sales of Luliconazole in other overseas markets
According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL (605177.SH) announced that it has recently received the active pharmaceutical ingredient registration certificate from the Korean Ministry of Food and Drug Safety (Korea MFDS) for the product name: Luliconazole. Luliconazole is used to treat superficial fungal infections of the skin caused by susceptible fungi, such as tinea pedis, tinea corporis, and tinea cruris, and can also be used for cutaneous candidiasis and tinea versicolor.
The company's Luliconazole active pharmaceutical ingredient has obtained the registration certificate in Korea, marking the company's qualification for market entry in Korea, which will have a positive impact on the company's expansion into the Korean pharmaceutical market, thereby promoting the sales of Luliconazole active pharmaceutical ingredient in other overseas markets